Alkermes (NASDAQ:ALKS – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 2.800-2.800 for the period, compared to the consensus EPS estimate of 2.670. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.
Alkermes Price Performance
Shares of NASDAQ ALKS traded down $0.76 during midday trading on Friday, hitting $26.09. The stock had a trading volume of 3,206,881 shares, compared to its average volume of 1,847,062. The company has a market capitalization of $4.41 billion, a PE ratio of 10.31, a P/E/G ratio of 0.56 and a beta of 0.46. The stock has a 50 day simple moving average of $27.83 and a 200-day simple moving average of $25.87. Alkermes has a 1 year low of $22.06 and a 1 year high of $32.88. The company has a quick ratio of 2.61, a current ratio of 2.99 and a debt-to-equity ratio of 0.22.
Alkermes (NASDAQ:ALKS – Get Free Report) last posted its quarterly earnings results on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The firm had revenue of $399.13 million during the quarter, compared to analysts’ expectations of $393.30 million. During the same quarter last year, the firm earned $0.38 earnings per share. The business’s revenue for the quarter was down 35.4% on a year-over-year basis. On average, sell-side analysts expect that Alkermes will post 2.36 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Report on ALKS
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
- Five stocks we like better than Alkermes
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Are the U.K. Market Holidays? How to Invest and Trade
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.